Trade press reports that food brands are adopting 'GLP-1 friendly' claims cautiously

Consumer-packaged-goods brands are courting the growing number of Americans on GLP-1 medications, but they are doing it carefully, according to trade publication FoodNavigator ^[1]. Rather than printing "GLP-1-friendly" directly on packaging, many companies are using coded language, such as "high protein" or "supports muscle mass," to signal that a product fits the needs of someone taking a drug like semaglutide or tirzepatide ^[1].

The caution stems from a basic gap: there is no regulatory definition of what "GLP-1-friendly" means, and the line between an ordinary marketing descriptor and an implied health claim is unsettled ^[1]. That ambiguity puts brands in a tricky spot. A claim that reads like a nutrition fact might be fine, but a claim that suggests the product treats a condition or interacts with a medication could invite more scrutiny ^[1].

Consumer research cited in the report shows the messaging choice is not just a legal question, it is also a marketing gamble ^[1]. Including a visible "GLP-1" badge or explicit messaging on a package can have what the report describes as a polarizing effect on shoppers, appealing to some and turning off others ^[1]. That split reaction is part of why companies are testing softer, less direct language instead of naming the drug class outright ^[1].

The FoodNavigator report also points to broader shifts in how GLP-1 use is changing what people buy. A separate Acosta Group analysis referenced in the coverage found that GLP-1 users are altering their relationship with food and how they feel about their own appearance, a trend companies are trying to capture with reformulated products ^[1]. Other reporting in the same outlet has tracked category-specific effects, including reduced spending on high-fat dairy items like cheese, butter and ice cream among GLP-1 users ^[1].

Why it matters for patients

For people taking semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), grocery store shelves are starting to reflect their reduced appetites and changed food preferences, even if the packaging does not say so directly ^[1]. That means shoppers may see more high-protein, muscle-support, or portion-adjusted products marketed toward them, but the absence of a clear "GLP-1-friendly" label makes it hard to know exactly which products are designed with GLP-1 users in mind and why ^[1].

Because no US agency has defined the term, patients cannot rely on package labeling alone to judge whether a food genuinely suits their needs while on these medications, such as easier digestion, adequate protein intake, or smaller portion sizes. The coded marketing language described in the report, like "high protein" instead of "GLP-1-friendly," may also make it harder for patients to search for or compare products explicitly aimed at their situation ^[1].

The polarized consumer reaction to overt GLP-1 messaging noted in the report suggests that some patients may prefer products that avoid the label altogether, while others might want clearer signposting ^[1]. Until a standard exists, patients navigating grocery aisles are left to interpret marketing terms without a shared definition of what "GLP-1-friendly" actually guarantees ^[1].

What happens next

The report does not indicate that any US regulator has proposed or is currently drafting a formal definition for "GLP-1-friendly" claims, so the labeling gap described by FoodNavigator remains unresolved as of the April 21, 2026 report ^[1]. It is not yet known from available sources whether the Food and Drug Administration or another body plans to address the ambiguity, or when that might happen ^[1].